The latest price target for Anavex Life Sciences (NASDAQ:AVXL) was reported by D. Boral Capital on March 31, 2026. The analyst firm set a price target for $24.00 expecting AVXL to rise to within 12 months (a possible 860.00% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Anavex Life Sciences (NASDAQ:AVXL) was provided by D. Boral Capital, and Anavex Life Sciences maintained their buy rating.

There is no last upgrade for Anavex Life Sciences

The last downgrade for Anavex Life Sciences Corp happened on October 24, 2025 when Jones Trading changed their price target from N/A to N/A for Anavex Life Sciences Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on March 31, 2026 so you should expect the next rating to be made available sometime around March 31, 2027.

While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a maintained with a price target of $24.00 to $24.00. The current price Anavex Life Sciences (AVXL) is trading at is $2.50, which is out of the analyst’s predicted range.